| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 4
Evaluation of the differences between acute and chronic asthma models with OVA/Alum exposure
1 Istanbul University, Institute of Health Sciences, Department of Biochemistry, Istanbul, Türkiye2 Bezmialem University, Faculty of Pharmacy, Department of Biochemistry, Istanbul, Türkiye
DOI : 10.23893/1307-2080.APS6246 Viewed : 3403 - Downloaded : 1094 This review article discusses the differences between animal models using ovalbumin (OVA) and aluminum hydroxide (alum). OVA, derived from chicken eggs, is a widely used allergen due to its low cost and high purity. Environmental sensitization and/or using an adjuvant such as alum is required to induce an asthma-like response. Animal species and strain, as well as sex selection, influence the development of allergic airway inflammation and other asthmarelated features in vivo models. Acute asthma models include OVA and alum to elicit airway inflammation, elevated IgE levels, and airway hyperresponsiveness. However, these models have limitations as they do not fully mimic the chronic inflammation and airway remodeling observed in human asthma. On the other hand, chronic asthma models involve prolonged exposure to low concentrations of allergens and have been shown to exhibit persistent airway hyperresponsiveness, airway remodeling, and other critical features of asthma. The aforementioned models have provided valuable insights into the pathophysiology of asthma and have been used to evaluate potential therapeutic agents. Overall, the use of OVA and alum in animal models has improved our understanding of asthma, and it is hoped that it has the potential to guide clinical therapies in the future. Keywords : OVA, alum, asthma, in vivo models, mouse